Stephen Smith, MD
Family Medicine · Morganton, NCNPI 1982646923
Payments from drug & device makers
Across 696 payments — averaging $1588.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$881K
- Lexicon Pharmaceuticals, Inc.$74K
- Novartis$55K
- Chiesi USA, Inc.$31K
- AstraZeneca$23K
- Eli Lilly$12K
- plus $29K from 21 others
Across 16 payments — averaging $182.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3K
- Eli Lilly$143
What the payments were for
- Travel & lodging$2,84556%
- Food & beverage$2,23744%
- Education$120%
- Other$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 581 | $881,138 |
| Lexicon Pharmaceuticals, Inc. | 1 | $74,114 |
| Novartis | 4 | $55,070 |
| Chiesi USA, Inc. | 4 | $30,500 |
| AstraZeneca | 20 | $23,093 |
| Eli Lilly | 29 | $12,180 |
| Ironwood Pharmaceuticals, Inc | 2 | $11,922 |
| Janssen Research & Development, LLC | 3 | $11,824 |
| Pfizer | 13 | $2,744 |
| Sanofi US Services Inc. | 1 | $1,856 |
| AbbVie | 11 | $173 |
| Novo Nordisk | 7 | $139 |
| Inspire Medical Systems, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $78 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| GSK | 2 | $39 |
| Johnson & Johnson | 1 | $38 |
| Medtronic | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Genentech USA, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Merck | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$124
How this compares
$1,105,271 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $195,557 |
| OzempicSemaglutide | 171 | $195,228 |
| MounjaroTirzepatide | 131 | $171,562 |
| JardianceEmpagliflozin | 183 | $148,288 |
| XareltoRivaroxaban | 86 | $75,758 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $61,129 |
| RybelsusSemaglutide | 44 | $57,427 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 65 | $56,217 |
| Repatha SureclickEvolocumab | 43 | $36,840 |
| OxycontinOxycodone Hcl | 29 | $35,128 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $32,899 |
| LinzessLinaclotide | 38 | $29,280 |
| EntrestoSacubitril/Valsartan | 45 | $27,157 |
| TrintellixVortioxetine Hydrobromide | 41 | $26,677 |
| Xtampza ErOxycodone Myristate | 26 | $22,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba | $139 | $262,121226 claims |
| PfizerEliquis | $2,744 | $195,557267 claims |
| Lilly USA, LLCMounjaro | $12 | $171,562131 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $15 | $153,844195 claims |
| Johnson & JohnsonXarelto | $38 | $75,75886 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $27 | $56,21765 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $39 | $47,420136 claims |
| AbbVieLinzess, Synthroid | $173 | $35,396140 claims |
| NovartisEntresto | $55,070 | $27,15745 claims |
| AstraZenecaFarxiga | $23,093 | $17,44328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Morganton
- Glenn GouldMorganton$540K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.